STOCKSCOUTER
StockScouter Premium
StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance
Learn more or Get it now! Stockscouter Portfolio performance
EVOK EVOKE PHARMA INCORPORATED StockScouter® Report
4
StockScouter® Score
EVOKE PHARMA INCORPORATED, a micro cap value company in the healthcare sector, is expected to underperform the market over the next six months with slightly higher than average risk
10 is the best possible rating. Learn more.
Summary
Positives
- Earnings growth in the past year is holding steady compared to earnings growth in the past three years. Neutral
- The enterprise value-to-sales ratio is approximately in line with that of comparably-sized companies in the StockScouter universe. Neutral
Concerns
- The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
- The multi-period measure of relative price change and consistency is well below average. Negative
Short-term Outlook
Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, value stocks will be out of favor, and healthcare stocks will be out of favor.
Expected Risk/Return
Core Model Grades
F
C
C
F